{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:09:32Z","timestamp":1790716172928,"version":"4.1.0"},"reference-count":130,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Causes of Schizophrenia: Immunology and Genetics Network"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Drug Safety"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>Cardiovascular disease (CVD) is one of the leading causes of death in patients with severe mental illness (SMI), being ~3.3 times higher than in the general population. The adverse cardiovascular effects of psychiatric medications have short- and long-term consequences that contribute to higher rates of cardiovascular death in patients experiencing SMI. By understanding these adverse effects, clinicians can better address cardiovascular health inequalities in patients with SMI from a pharmacological perspective. This review highlights both the short- and long-term adverse cardiovascular effects of psychiatric medications. These adverse effects include QTc prolongation and torsades de pointes (TdP), which are phenomena associated with certain selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs) and antipsychotics. Increasing QT dispersion and induction of Brugada phenotype, both associated with serious cardiac arrhythmias and sudden death, can occur with certain antipsychotics (e.g. trifluoperazine), certain TCAs (e.g. amitriptyline), certain SSRIs (e.g. fluoxetine), methylphenidate and particular mood stabilisers (e.g. lithium). Antipsychotics themselves are associated with increased risk of myocarditis, cardiomyopathy, tachycardia, cardiometabolic derangement, hypertension, orthostatic hypotension and bradycardia. Attention deficit Hyperactivity disorder (ADHD) medications contribute to CVD and tachycardia. Acetylcholinesterase inhibitors (AChEIs) contribute towards bradycardia. Hypertension risk is elevated with serotonin-norepinephrine reuptake inhibitors (SNRIs), norepinephrine-dopamine reuptake inhibitors (NDRIs), monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase A (RIMA) and psychostimulants. Conversely, orthostatic hypotension is associated with certain psychiatric medications, namely TCAs and serotonin antagonist and reuptake inhibitors (SARIs). It is important to note that pharmacokinetic drug-drug interactions, such as inhibition of the cytochrome P450 (CYP450) system, can affect the pharmacodynamic profile of psychiatric medications, thereby increasing the risk of their associated adverse cardiovascular effects. By understanding the main adverse cardiovascular effects of psychiatric medications and prescribing appropriately, clinicians can reduce potential harm in patients with SMI.<\/jats:p>","DOI":"10.1177\/20420986261418947","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T10:22:32Z","timestamp":1774779752000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Treating hearts and minds: adverse cardiovascular effects of psychiatric medications"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2586-2922","authenticated-orcid":false,"given":"Asdaq Shabbir","family":"Raja","sequence":"first","affiliation":[{"name":"Acute Medicine Unit, Raigmore Hospital, NHS Highland, Old Perth Road, Inverness IV2 3UJ, Scotland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Leslie","sequence":"additional","affiliation":[{"name":"Cardiac Unit, Raigmore Hospital, NHS Highland, Inverness, Scotland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Buist","sequence":"additional","affiliation":[{"name":"Advanced Clinical Pharmacist in Psychiatry, NHS Highland, Inverness, Scotland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon F.","family":"Rushworth","sequence":"additional","affiliation":[{"name":"Pharmacy, Highland &amp; Islands Pharmacy Education &amp; Research (HIPER), NHS Highland, Inverness, Scotland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian L.","family":"Megson","sequence":"additional","affiliation":[{"name":"University of St Andrews, St Andrews, Scotland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"McNamara","sequence":"additional","affiliation":[{"name":"Psychiatry, New Craigs Hospital, NHS Highland, Inverness, Scotland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,29]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"National Institute of Mental Health. Mental Illness https:\/\/www.nimh.nih.gov\/health\/statistics\/mental-illness#:~:text=Serious%20Mental%20Illness%20Serious%20mental%20illness%20%28SMI%29%20is among%20those%20who%20experience%20disability%20due%20to%20SMI (2024 accessed 12 September 2025)."},{"key":"e_1_3_4_3_2","unstructured":"Public Health England. Severe mental illness (SMI) and physical health inequalities: briefing https:\/\/www.gov.uk\/government\/publications\/severe-mental-illness-smi-physical-health-inequalities\/severe-mental-illness-and-physical-health-inequalities-briefing (2018 accessed 12 September 2025)"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20128"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.06.017"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae054"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e13930"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30416-X"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.704281"},{"issue":"4","key":"e_1_3_4_10_2","article-title":"Acute blood pressure changes associated with antipsychotic administration to psychiatric inpatients","volume":"20","author":"Parks KA","year":"2018","unstructured":"Parks KA, Parks CG, Yost JP, et al. Acute blood pressure changes associated with antipsychotic administration to psychiatric inpatients. Prim Care Companion CNS Disord 2018; 20(4): 18m02299.","journal-title":"Prim Care Companion CNS Disord"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.5498\/wjp.v11.i10.736"},{"issue":"3","key":"e_1_3_4_12_2","article-title":"Trends and prevalence of psychiatric medication use in children and adolescents in the period between 2013 and 2023: a systematic review","volume":"16","author":"Altuwairqi Y.","year":"2024","unstructured":"Altuwairqi Y. Trends and prevalence of psychiatric medication use in children and adolescents in the period between 2013 and 2023: a systematic review. Cureus 2024; 16(3): e55452.","journal-title":"Cureus"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/01612840.2025.2476156"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.4377"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.04.056"},{"issue":"9","key":"e_1_3_4_16_2","first-page":"11","article-title":"Psychiatric comorbidities in adult attention-deficit\/hyperactivity disorder: prevalence and patterns in the routine clinical setting","volume":"16","author":"Ohnishi T","year":"2019","unstructured":"Ohnishi T, Kobayashi H, Yajima T, et al. Psychiatric comorbidities in adult attention-deficit\/hyperactivity disorder: prevalence and patterns in the routine clinical setting. Innov Clin Neurosci 2019; 16(9\u201310): 11\u201316.","journal-title":"Innov Clin Neurosci"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2011.07.004"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2016.01.021"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9781615375264.lg01"},{"key":"e_1_3_4_20_2","unstructured":"Medicines & Healthcare products Regulatory Agency. Products https:\/\/products.mhra.gov.uk\/ (2025 accessed 12 September 2025)."},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.15420\/aer.2019.8.3.G1"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.039598"},{"key":"e_1_3_4_23_2","volume-title":"The Maudsley prescribing guidelines in psychiatry","author":"Taylor DM","year":"2024","unstructured":"Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 15th ed. Hoboken, NJ: Wiley Blackwell, 2024.","edition":"15"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042098618772979"},{"issue":"41","key":"e_1_3_4_25_2","first-page":"687","article-title":"QTc prolongation by psychiatric drugs and the risk of torsade de pointes","volume":"108","author":"Wenzel-Seifert K","year":"2011","unstructured":"Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychiatric drugs and the risk of torsade de pointes. Dtsch Arztebl Int 2011; 108(41): 687\u2013693.","journal-title":"Dtsch Arztebl Int"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.166619"},{"key":"e_1_3_4_27_2","unstructured":"CredibleMeds. Risk categories for drugs that prolong QT & induce torsades de pointes (TdP) crediblemeds.org\/druglist (2024 accessed 12 September 2025)."},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.11.1774"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.12.030"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.180.6.515"},{"key":"e_1_3_4_31_2","first-page":"5","article-title":"Thioridazine sale discontinued in Canada","volume":"4","author":"World Health Organization","year":"2005","unstructured":"World Health Organization. Thioridazine sale discontinued in Canada. WHO Pharmaceuticals Newsletter 4, 2005, p. 5.","journal-title":"WHO Pharmaceuticals Newsletter"},{"issue":"3","key":"e_1_3_4_32_2","first-page":"82","article-title":"Withdrawal of thioridazine","volume":"30","author":"Australian Prescriber Editorial Executive Committee","year":"2007","unstructured":"Australian Prescriber Editorial Executive Committee. Withdrawal of thioridazine. Aust Precr 2007; 30(3): 82.","journal-title":"Aust Precr"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3346"},{"key":"e_1_3_4_34_2","unstructured":"U.S. Food and Drug Administration. Thioridazine hydrochloride (application number 088004) https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=088004 (2025 accessed 9 December 2025)."},{"key":"e_1_3_4_35_2","unstructured":"DailyMed. Thioridazine hydrochloride https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=9c4bedb4-2d59-4fcd-aad7-fce988cd96d8#:~:text=Thioridazine%20hydrochloride%20tablets%20are%20indicated adverse%20effects%20from%20those%20drugs (2017 accessed 9 December 2025)."},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-8-57"},{"key":"e_1_3_4_37_2","unstructured":"Bazire S. Psychotropic drug directory 2024: the professionals\u2019 pocket handbook and aide memoire. 31st ed. Pharmaceutical Press https:\/\/www.medicinescomplete.com\/#\/browse\/pdd (2024 accessed 19 June 2025)."},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1208456"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2024.104209"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.4235\/agmr.21.0079"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.113.000152"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2020-138661"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0316-6"},{"issue":"5","key":"e_1_3_4_44_2","first-page":"465","article-title":"Impact of psychiatric drugs on QT interval dispersion in adult patients","volume":"102","author":"Claudio BDQ","year":"2014","unstructured":"Claudio BDQ, Costa MAN, Penna F, et al. Impact of psychiatric drugs on QT interval dispersion in adult patients. Arq Bras Cardiol 2014; 102(5): 465\u2013472.","journal-title":"Arq Bras Cardiol"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/joa3.12253"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-016-0864-y"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S287042"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.5152\/alphapsychiatry.2023.231185"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2020.09.003"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2021.12.001"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2016.03.016"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.joa.2013.02.002"},{"key":"e_1_3_4_53_2","unstructured":"Chung EH. Brugada syndrome. BMJ Best Practice https:\/\/bestpractice.bmj.com\/topics\/en-gb\/3000313\/history-exam (2023 accessed 12 September 2025)."},{"key":"e_1_3_4_54_2","first-page":"24","article-title":"Management of patients with a Brugada ECG pattern","volume":"7","author":"Brugada J.","year":"2009","unstructured":"Brugada J. Management of patients with a Brugada ECG pattern. e-Journal Cardiol Pract 2009; 7: 24.","journal-title":"e-Journal Cardiol Pract"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2009.07.002"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1080\/15563650802293984"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2008.153346"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.resuscitation.2021.10.022"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-00435-x"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147722"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2017.11.246"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2032659"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13017"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1177\/0706743718816058"},{"key":"e_1_3_4_65_2","unstructured":"Van Egerschot AB Jollie-Helthuis M. Zaponex fact sheet myocarditis and cardiomyopathy. ZTAS https:\/\/www.ztas.com\/PDF\/FS_Myocarditis_cardiomyopathy_jan2021.pdf (2021 accessed 12 Sep 2025)."},{"key":"e_1_3_4_66_2","unstructured":"Datapharm Ltd. Electronic Medicines Compendium. London: Datapharm Ltd https:\/\/www.medicines.org.uk\/emc (2025 accessed 12 September 2025)."},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.08.018"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13398"},{"key":"e_1_3_4_69_2","unstructured":"New South Wales Ministry of Health. Monitoring clozapine-induced myocarditis guideline https:\/\/www1.health.nsw.gov.au\/pds\/ActivePDSDocuments\/GL2022_011.pdf (2022 accessed 12 September 2025)."},{"key":"e_1_3_4_70_2","unstructured":"Deshpande SR Das B. Myocarditis: Investigations. BMJ Best Practice https:\/\/bestpractice.bmj.com\/topics\/en-gb\/244\/investigations (2024 accessed 12 Sep 2025)."},{"key":"e_1_3_4_71_2","unstructured":"McKeown P Muir A. Assessment of cardiomyopathy. BMJ Best Practice https:\/\/bestpractice.bmj.com\/topics\/en-gb\/371\/diagnosis-approach (2024 accessed 12 September 2025)."},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2023.09.039"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjco.2020.11.017"},{"key":"e_1_3_4_74_2","unstructured":"Calderwood C Mitchell J. National standard for monitoring the physical health of people being treated with clozapine. NHS Scotland \u2013 Publications https:\/\/www.publications.scot.nhs.uk\/files\/cmo-2017-04.pdf (2017 accessed 12 September 2025)."},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2024.104172"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104123"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11123295"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.4294"},{"issue":"4","key":"e_1_3_4_79_2","doi-asserted-by":"crossref","DOI":"10.1016\/S0002-9149(98)00031-9","article-title":"Hypertriglyceridemia as a cardiovascular risk factor","volume":"81","author":"Austin MA","year":"1998","unstructured":"Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81(4A): 7B\u201312B.","journal-title":"Am J Cardiol"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116645254"},{"key":"e_1_3_4_81_2","unstructured":"National Institute for Health and Care Excellence. Scenario: assessing cardiovascular risk. NICE https:\/\/cks.nice.org.uk\/topics\/cvd-risk-assessment-management\/management\/cvd-risk-assessment\/ (2025 accessed 12 September 2025)."},{"key":"e_1_3_4_82_2","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","volume":"357","author":"Hippisley-Cox J","year":"2017","unstructured":"Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 2017; 357: j2099.","journal-title":"BMJ"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.2133"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018181"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(23)00262-6"},{"key":"e_1_3_4_86_2","unstructured":"Psymatik. Antipsychotic and antidepressant treatment optimiser https:\/\/www.psymatik.com\/ (2024 accessed 12 September 2025)."},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13769"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.2525"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.a2019.0021"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v59n1002"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0514"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-020-01096-4"},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0410-7"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-018-1932-y"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.1177\/1178646919873925"},{"key":"e_1_3_4_96_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.121.010573"},{"key":"e_1_3_4_97_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-020-00796-5"},{"issue":"5","key":"e_1_3_4_98_2","first-page":"617","article-title":"Adverse effects of antipsychotic medications","volume":"81","author":"Muench J","year":"2010","unstructured":"Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician 2010; 81(5): 617\u2013622.","journal-title":"Am Fam Physician"},{"key":"e_1_3_4_99_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003821"},{"key":"e_1_3_4_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2019.10.032"},{"key":"e_1_3_4_101_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy037"},{"key":"e_1_3_4_102_2","unstructured":"National Institute for Healthcare and Care Excellence. Postural hypotension in adults: fludrocortisone https:\/\/www.nice.org.uk\/advice\/esuom20\/chapter\/Intervention-and-alternatives (2024 accessed 12 September 2025)"},{"key":"e_1_3_4_103_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-016-0363-9"},{"key":"e_1_3_4_104_2","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000169"},{"key":"e_1_3_4_105_2","doi-asserted-by":"publisher","DOI":"10.1192\/bja.2019.49"},{"key":"e_1_3_4_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.03.416"},{"key":"e_1_3_4_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.10.025"},{"key":"e_1_3_4_108_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.144808"},{"key":"e_1_3_4_109_2","doi-asserted-by":"publisher","DOI":"10.1177\/10398562231224156"},{"key":"e_1_3_4_110_2","doi-asserted-by":"publisher","DOI":"10.1177\/20451253221097261"},{"key":"e_1_3_4_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(25)00062-8"},{"key":"e_1_3_4_112_2","doi-asserted-by":"publisher","DOI":"10.1177\/20451253241243297"},{"key":"e_1_3_4_113_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjment-2023-300730"},{"issue":"8","key":"e_1_3_4_114_2","article-title":"2018 ACC\/AHA\/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"140","author":"Kusumoto FM","year":"2019","unstructured":"Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC\/AHA\/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circ 2019; 140(8): e382\u2013e482.","journal-title":"Circ"},{"key":"e_1_3_4_115_2","doi-asserted-by":"publisher","DOI":"10.2190\/U99G-XDML-0GRG-BYE0"},{"issue":"5","key":"e_1_3_4_116_2","article-title":"A rare case of risperidone-induced hypothermia and thrombocytopenia","volume":"14","author":"Goyal L","year":"2022","unstructured":"Goyal L, Acebo R, Islam S, et al. A rare case of risperidone-induced hypothermia and thrombocytopenia. Cureus 2022; 14(5): e24836.","journal-title":"Cureus"},{"key":"e_1_3_4_117_2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-234999"},{"key":"e_1_3_4_118_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-020-02695-w"},{"key":"e_1_3_4_119_2","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000244"},{"key":"e_1_3_4_120_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612043383872"},{"issue":"4","key":"e_1_3_4_121_2","first-page":"169","article-title":"Cardiovascular considerations in antidepressant therapy: an evidence-based review","volume":"8","author":"Yekehtaz H","year":"2013","unstructured":"Yekehtaz H, Farokhnia M, Akhondzadeh S. Cardiovascular considerations in antidepressant therapy: an evidence-based review. J Tehran Heart Cent 2013; 8(4): 169\u2013176.","journal-title":"J Tehran Heart Cent"},{"key":"e_1_3_4_122_2","unstructured":"Khalid MM Waseem M. Tricyclic antidepressant toxicity. Treasure Island FL: StatPearls Publishing https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK430931\/ (2023 accessed 12 September 2025)."},{"key":"e_1_3_4_123_2","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.622"},{"key":"e_1_3_4_124_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.43"},{"key":"e_1_3_4_125_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2009.02488.x"},{"key":"e_1_3_4_126_2","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.3311"},{"key":"e_1_3_4_127_2","doi-asserted-by":"publisher","DOI":"10.3390\/genes11111295"},{"key":"e_1_3_4_128_2","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.7860"},{"key":"e_1_3_4_129_2","unstructured":"Flockhart DA Thacker D McDonald C et al. The Flockhart cytochrome P450 drug-drug interaction table https:\/\/drug-interactions.medicine.iu.edu\/ (2021 accessed 12 September 2025)."},{"key":"e_1_3_4_130_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy8020063"},{"key":"e_1_3_4_131_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004216"}],"container-title":["Therapeutic Advances in Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420986261418947","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20420986261418947","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420986261418947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:41:22Z","timestamp":1777592482000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20420986261418947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":130,"alternative-id":["10.1177\/20420986261418947"],"URL":"https:\/\/doi.org\/10.1177\/20420986261418947","relation":{},"ISSN":["2042-0986","2042-0994"],"issn-type":[{"value":"2042-0986","type":"print"},{"value":"2042-0994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"article-number":"20420986261418947"}}